Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy.

Ulldemolins M, Lipman J, Liu X, Abdul-Aziz MH, Baptista JP, Bilgrami I, Bitker L, Boidin C, Brinkmann A, Cheng V, Choi G, Cole CL, De Waele JJ, Deans R, Eastwood GM, Escobar L, Frey OR, Garreau R, Goutelle S, Gresham R, Hernandez-Mitre MP, Jamal JA, Joynt GM, Kanji S, Kielstein JT, Kluge S, König C, Koulouras VP, Lassig-Smith M, Laterre PF, Lee A, Lefrant JY, Lei K, Leung P, Mat-Nor MB, Mudaliar Y, Ostermann M, Paul SK, Peake SL, Rello J, Richard JC, Richards B, Roberts DM, Roberts MS, Roehr AC, Roger C, Seoane L, Shekar K, Sinnollareddy M, Sousa E, Spring A, Starr T, Stephens D, Taccone FS, Thomas J, Turnidge J, Valkonen M, Wallis SC, Williams T, Wittebole X, Wright DFB, Zikou XT, Roberts JA, SMARRT Study Collaborators, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Groups for Infections in Critically Ill Patients (ESGCIP) and the ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

Open source

DOI: 10.1186/s13054-026-06226-z
Published: 2026 Aug 4
Container: Critical care (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13054-026-06226-z,
  title = {Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy.},
  author = {Ulldemolins M and Lipman J and Liu X and Abdul-Aziz MH and Baptista JP and Bilgrami I and Bitker L and Boidin C and Brinkmann A and Cheng V and Choi G and Cole CL and De Waele JJ and Deans R and Eastwood GM and Escobar L and Frey OR and Garreau R and Goutelle S and Gresham R and Hernandez-Mitre MP and Jamal JA and Joynt GM and Kanji S and Kielstein JT and Kluge S and König C and Koulouras VP and Lassig-Smith M and Laterre PF and Lee A and Lefrant JY and Lei K and Leung P and Mat-Nor MB and Mudaliar Y and Ostermann M and Paul SK and Peake SL and Rello J and Richard JC and Richards B and Roberts DM and Roberts MS and Roehr AC and Roger C and Seoane L and Shekar K and Sinnollareddy M and Sousa E and Spring A and Starr T and Stephens D and Taccone FS and Thomas J and Turnidge J and Valkonen M and Wallis SC and Williams T and Wittebole X and Wright DFB and Zikou XT and Roberts JA and SMARRT Study Collaborators and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Groups for Infections in Critically Ill Patients (ESGCIP) and the ESCMID PK/PD of Anti-Infectives Study Group (EPASG)},
  year = {2026},
  journal = {Critical care (London, England)},
  doi = {10.1186/s13054-026-06226-z},
  url = {https://doi.org/10.1186/s13054-026-06226-z}
}

RIS

TY  - JOUR
TI  - Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy.
AU  - Ulldemolins M
AU  - Lipman J
AU  - Liu X
AU  - Abdul-Aziz MH
AU  - Baptista JP
AU  - Bilgrami I
AU  - Bitker L
AU  - Boidin C
AU  - Brinkmann A
AU  - Cheng V
AU  - Choi G
AU  - Cole CL
AU  - De Waele JJ
AU  - Deans R
AU  - Eastwood GM
AU  - Escobar L
AU  - Frey OR
AU  - Garreau R
AU  - Goutelle S
AU  - Gresham R
AU  - Hernandez-Mitre MP
AU  - Jamal JA
AU  - Joynt GM
AU  - Kanji S
AU  - Kielstein JT
AU  - Kluge S
AU  - König C
AU  - Koulouras VP
AU  - Lassig-Smith M
AU  - Laterre PF
AU  - Lee A
AU  - Lefrant JY
AU  - Lei K
AU  - Leung P
AU  - Mat-Nor MB
AU  - Mudaliar Y
AU  - Ostermann M
AU  - Paul SK
AU  - Peake SL
AU  - Rello J
AU  - Richard JC
AU  - Richards B
AU  - Roberts DM
AU  - Roberts MS
AU  - Roehr AC
AU  - Roger C
AU  - Seoane L
AU  - Shekar K
AU  - Sinnollareddy M
AU  - Sousa E
AU  - Spring A
AU  - Starr T
AU  - Stephens D
AU  - Taccone FS
AU  - Thomas J
AU  - Turnidge J
AU  - Valkonen M
AU  - Wallis SC
AU  - Williams T
AU  - Wittebole X
AU  - Wright DFB
AU  - Zikou XT
AU  - Roberts JA
AU  - SMARRT Study Collaborators
AU  - European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Groups for Infections in Critically Ill Patients (ESGCIP) and the ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
PY  - 2026
JO  - Critical care (London, England)
DO  - 10.1186/s13054-026-06226-z
UR  - https://doi.org/10.1186/s13054-026-06226-z
ER  -

APA

M, U., J, L., X, L., MH, A., JP, B., I, B., L, B., C, B., A, B., V, C., G, C., CL, C., JJ, D. W., R, D., GM, E., L, E., OR, F., R, G., S, G., R, G., MP, H., JA, J., GM, J., S, K., JT, K., S, K., C, K., VP, K., M, L., PF, L., A, L., JY, L., K, L., P, L., MB, M., Y, M., M, O., SK, P., SL, P., J, R., JC, R., B, R., DM, R., MS, R., AC, R., C, R., L, S., K, S., M, S., E, S., A, S., T, S., D, S., FS, T., J, T., J, T., M, V., SC, W., T, W., X, W., DFB, W., XT, Z., JA, R., Collaborators, S. S., & (EPASG), E. S. O. C. M. A. I. D. (. S. G. F. I. I. C. I. P. (. A. T. E. P. O. A. S. G. (2026). Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy.. Critical care (London, England). https://doi.org/10.1186/s13054-026-06226-z

Source records

pubmed · retrieved 2026-09-26T04:32:21.881Z